Richard Boismenu

Richard was one of Wendy Havran’s first post-doctoral fellows. Together, they pioneered the field of innate gamma/delta TCR T cells and defined critical roles for these cells in mucosal immune defense, inflammation and wound healing.

Before joining IgGenix, Richard served as Vice President and Head of Product Development, and Chair of the Portfolio Strategy Committee at Coherus Biosciences. Prior to this appointment, he was a Project Team Leader at Genentech, where he led programs in immunology, ophthalmology and metabolic disorder research. Before Genentech, Dr. Boismenu was Senior Director of the Immunology and Cell Biology Group at Repligen Corporation. Richard started his independent research career as an Assistant Professor of Immunology at The Scripps Research Institute where he had previously been a postdoctoral fellow in Wendy Havran’s laboratory.

Education

• Senior Post-Doctoral Fellow The Scripps Research Institute (1995 — 1996)
• Post-Doctoral Fellow The Scripps Research Institute (1992 — 1995)
• Ph.D. McGill University (1984 — 1992)
• B.Sc. Université de Montréal (1982 — 1984)

Companies

• Membership Committee Member The American Association of Immunologists (2021)
• EFL Life Sciences Mentor NYU Stern School of Business (2021)
• Chief Scientific Officer IgGenix, Inc (2020)
• Vice President, Head Of Product Development Coherus BioSciences (2018 — 2020)
• Founder and President Aldehyde Group I Biopharma Advisory (2018 — 2019)
• Project Team Leader, Portfolio Management & Operations Genentech (2010 — 2017)
• Senior Development Team Leader, Development Sciences Genentech (2006 — 2010)
• Senior Director Repligen Corporation (2001 — 2006)
• Assistant Professor of Immunology The Scripps Research Institute (1996 — 2000)